Travere Therapeutics Reports Third Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Travere Therapeutics (TVTX) PT Raised to $33 at Evercore ISI
October 31, 2024 4:21 PM EDTEvercore ISI analyst Liisa Bayko raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $33.00 (from $30.00) while maintaining a Outperform rating.
The analyst comments "TVTX posted a nice beat with Filspari sales reaching $35.6M, ~10% beat to $32.9M consensus and 31% q/q growth.... More
